PittsburghV1, Main, Exploration, bibRecord, 000656

A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.

Identifieur interne : 000656 ( Main/Exploration ); précédent : 000655; suivant : 000657

A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.

Auteurs : Victoria Plamadeala [États-Unis] ; Joseph L. Kelley [États-Unis] ; John K. Chan [États-Unis] ; Thomas C. Krivak [États-Unis] ; Michael J. Gabrin [États-Unis] ; Stacey L. Brower [États-Unis] ; Matthew A. Powell [États-Unis] ; Thomas J. Rutherford [États-Unis] ; Robert L. Coleman [États-Unis]

Source :

Gynecologic oncology [ 1095-6859 ] ; 2015.

RBID : pubmed:25462203

Descripteurs français

English descriptors

KwdEn :
- Cohort Studies, Cost-Benefit Analysis, Drug Resistance, Neoplasm, Female, Gynecologic Surgical Procedures (economics), Humans, Markov Chains, Models, Economic, Neoplasm Recurrence, Local (drug therapy), Neoplasm Recurrence, Local (economics), Neoplasm Recurrence, Local (surgery), Neoplasms, Glandular and Epithelial (drug therapy), Neoplasms, Glandular and Epithelial (economics), Neoplasms, Glandular and Epithelial (surgery), Organoplatinum Compounds (administration & dosage), Organoplatinum Compounds (adverse effects), Organoplatinum Compounds (economics), Ovarian Neoplasms (drug therapy), Ovarian Neoplasms (economics), Ovarian Neoplasms (surgery), Proportional Hazards Models, Survival Rate, United States.
MESH :
- chemical , administration & dosage : Organoplatinum Compounds.
- chemical , adverse effects : Organoplatinum Compounds.
- geographic : United States.
- drug therapy : Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms.
- economics : Gynecologic Surgical Procedures, Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Organoplatinum Compounds, Ovarian Neoplasms.
- surgery : Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms.
- Cohort Studies, Cost-Benefit Analysis, Drug Resistance, Neoplasm, Female, Humans, Markov Chains, Models, Economic, Proportional Hazards Models, Survival Rate.

Abstract

Clinical validation of a chemoresponse assay was recently published, demonstrating a significant increase in overall survival in recurrent ovarian cancer patients treated with therapies to which their tumor was sensitive in the assay. The current study investigates the cost effectiveness of using the assay at the time of ovarian cancer recurrence from the payer's perspective.

DOI: 10.1016/j.ygyno.2014.11.019
PubMed: 25462203

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.</title>
<author><name sortKey="Plamadeala, Victoria" sort="Plamadeala, Victoria" uniqKey="Plamadeala V" first="Victoria" last="Plamadeala">Victoria Plamadeala</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kelley, Joseph L" sort="Kelley, Joseph L" uniqKey="Kelley J" first="Joseph L" last="Kelley">Joseph L. Kelley</name>
<affiliation wicri:level="2"><nlm:affiliation>Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Magee-Womens Hospital of UPMC, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chan, John K" sort="Chan, John K" uniqKey="Chan J" first="John K" last="Chan">John K. Chan</name>
<affiliation wicri:level="2"><nlm:affiliation>Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Krivak, Thomas C" sort="Krivak, Thomas C" uniqKey="Krivak T" first="Thomas C" last="Krivak">Thomas C. Krivak</name>
<affiliation wicri:level="2"><nlm:affiliation>The Western Pennsylvania Hospital, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Western Pennsylvania Hospital, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gabrin, Michael J" sort="Gabrin, Michael J" uniqKey="Gabrin M" first="Michael J" last="Gabrin">Michael J. Gabrin</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brower, Stacey L" sort="Brower, Stacey L" uniqKey="Brower S" first="Stacey L" last="Brower">Stacey L. Brower</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States. Electronic address: sbrower@helomics.com.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Powell, Matthew A" sort="Powell, Matthew A" uniqKey="Powell M" first="Matthew A" last="Powell">Matthew A. Powell</name>
<affiliation wicri:level="4"><nlm:affiliation>Washington University School of Medicine, St. Louis, MO, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Washington University School of Medicine, St. Louis, MO</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Rutherford, Thomas J" sort="Rutherford, Thomas J" uniqKey="Rutherford T" first="Thomas J" last="Rutherford">Thomas J. Rutherford</name>
<affiliation wicri:level="2"><nlm:affiliation>Yale University School of Medicine, New Haven, CT, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Yale University School of Medicine, New Haven, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coleman, Robert L" sort="Coleman, Robert L" uniqKey="Coleman R" first="Robert L" last="Coleman">Robert L. Coleman</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Texas MD Anderson Cancer Center, Houston, TX, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25462203</idno>
<idno type="pmid">25462203</idno>
<idno type="doi">10.1016/j.ygyno.2014.11.019</idno>
<idno type="wicri:Area/PubMed/Corpus">000818</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000818</idno>
<idno type="wicri:Area/PubMed/Curation">000818</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000818</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000818</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000818</idno>
<idno type="wicri:Area/Ncbi/Merge">004209</idno>
<idno type="wicri:Area/Ncbi/Curation">004209</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004209</idno>
<idno type="wicri:Area/Main/Merge">000656</idno>
<idno type="wicri:Area/Main/Curation">000656</idno>
<idno type="wicri:Area/Main/Exploration">000656</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.</title>
<author><name sortKey="Plamadeala, Victoria" sort="Plamadeala, Victoria" uniqKey="Plamadeala V" first="Victoria" last="Plamadeala">Victoria Plamadeala</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kelley, Joseph L" sort="Kelley, Joseph L" uniqKey="Kelley J" first="Joseph L" last="Kelley">Joseph L. Kelley</name>
<affiliation wicri:level="2"><nlm:affiliation>Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Magee-Womens Hospital of UPMC, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chan, John K" sort="Chan, John K" uniqKey="Chan J" first="John K" last="Chan">John K. Chan</name>
<affiliation wicri:level="2"><nlm:affiliation>Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Krivak, Thomas C" sort="Krivak, Thomas C" uniqKey="Krivak T" first="Thomas C" last="Krivak">Thomas C. Krivak</name>
<affiliation wicri:level="2"><nlm:affiliation>The Western Pennsylvania Hospital, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Western Pennsylvania Hospital, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gabrin, Michael J" sort="Gabrin, Michael J" uniqKey="Gabrin M" first="Michael J" last="Gabrin">Michael J. Gabrin</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brower, Stacey L" sort="Brower, Stacey L" uniqKey="Brower S" first="Stacey L" last="Brower">Stacey L. Brower</name>
<affiliation wicri:level="2"><nlm:affiliation>Helomics™ Corporation, Pittsburgh, PA, United States. Electronic address: sbrower@helomics.com.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Helomics™ Corporation, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Powell, Matthew A" sort="Powell, Matthew A" uniqKey="Powell M" first="Matthew A" last="Powell">Matthew A. Powell</name>
<affiliation wicri:level="4"><nlm:affiliation>Washington University School of Medicine, St. Louis, MO, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Washington University School of Medicine, St. Louis, MO</wicri:regionArea>
<placeName><region type="state">Missouri (État)</region>
<settlement type="city">Saint-Louis (Missouri)</settlement>
</placeName>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
</affiliation>
</author>
<author><name sortKey="Rutherford, Thomas J" sort="Rutherford, Thomas J" uniqKey="Rutherford T" first="Thomas J" last="Rutherford">Thomas J. Rutherford</name>
<affiliation wicri:level="2"><nlm:affiliation>Yale University School of Medicine, New Haven, CT, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Yale University School of Medicine, New Haven, CT</wicri:regionArea>
<placeName><region type="state">Connecticut</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coleman, Robert L" sort="Coleman, Robert L" uniqKey="Coleman R" first="Robert L" last="Coleman">Robert L. Coleman</name>
<affiliation wicri:level="2"><nlm:affiliation>University of Texas MD Anderson Cancer Center, Houston, TX, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Gynecologic oncology</title>
<idno type="eISSN">1095-6859</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cohort Studies</term>
<term>Cost-Benefit Analysis</term>
<term>Drug Resistance, Neoplasm</term>
<term>Female</term>
<term>Gynecologic Surgical Procedures (economics)</term>
<term>Humans</term>
<term>Markov Chains</term>
<term>Models, Economic</term>
<term>Neoplasm Recurrence, Local (drug therapy)</term>
<term>Neoplasm Recurrence, Local (economics)</term>
<term>Neoplasm Recurrence, Local (surgery)</term>
<term>Neoplasms, Glandular and Epithelial (drug therapy)</term>
<term>Neoplasms, Glandular and Epithelial (economics)</term>
<term>Neoplasms, Glandular and Epithelial (surgery)</term>
<term>Organoplatinum Compounds (administration & dosage)</term>
<term>Organoplatinum Compounds (adverse effects)</term>
<term>Organoplatinum Compounds (economics)</term>
<term>Ovarian Neoplasms (drug therapy)</term>
<term>Ovarian Neoplasms (economics)</term>
<term>Ovarian Neoplasms (surgery)</term>
<term>Proportional Hazards Models</term>
<term>Survival Rate</term>
<term>United States</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term>
<term>Chaines de Markov</term>
<term>Composés organiques du platine (administration et posologie)</term>
<term>Composés organiques du platine (effets indésirables)</term>
<term>Composés organiques du platine (économie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Modèles de hasards proportionnels</term>
<term>Modèles économiques</term>
<term>Procédures de chirurgie gynécologique (économie)</term>
<term>Récidive tumorale locale ()</term>
<term>Récidive tumorale locale (traitement médicamenteux)</term>
<term>Récidive tumorale locale (économie)</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Taux de survie</term>
<term>Tumeurs de l'ovaire ()</term>
<term>Tumeurs de l'ovaire (traitement médicamenteux)</term>
<term>Tumeurs de l'ovaire (économie)</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires ()</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires (traitement médicamenteux)</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires (économie)</term>
<term>États-Unis d'Amérique</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Organoplatinum Compounds</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Organoplatinum Compounds</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Composés organiques du platine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasm Recurrence, Local</term>
<term>Neoplasms, Glandular and Epithelial</term>
<term>Ovarian Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Gynecologic Surgical Procedures</term>
<term>Neoplasm Recurrence, Local</term>
<term>Neoplasms, Glandular and Epithelial</term>
<term>Organoplatinum Compounds</term>
<term>Ovarian Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Composés organiques du platine</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Neoplasm Recurrence, Local</term>
<term>Neoplasms, Glandular and Epithelial</term>
<term>Ovarian Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Récidive tumorale locale</term>
<term>Tumeurs de l'ovaire</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Composés organiques du platine</term>
<term>Procédures de chirurgie gynécologique</term>
<term>Récidive tumorale locale</term>
<term>Tumeurs de l'ovaire</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cohort Studies</term>
<term>Cost-Benefit Analysis</term>
<term>Drug Resistance, Neoplasm</term>
<term>Female</term>
<term>Humans</term>
<term>Markov Chains</term>
<term>Models, Economic</term>
<term>Proportional Hazards Models</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term>
<term>Chaines de Markov</term>
<term>Femelle</term>
<term>Humains</term>
<term>Modèles de hasards proportionnels</term>
<term>Modèles économiques</term>
<term>Récidive tumorale locale</term>
<term>Résistance aux médicaments antinéoplasiques</term>
<term>Taux de survie</term>
<term>Tumeurs de l'ovaire</term>
<term>Tumeurs épithéliales épidermoïdes et glandulaires</term>
<term>États-Unis d'Amérique</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Clinical validation of a chemoresponse assay was recently published, demonstrating a significant increase in overall survival in recurrent ovarian cancer patients treated with therapies to which their tumor was sensitive in the assay. The current study investigates the cost effectiveness of using the assay at the time of ovarian cancer recurrence from the payer's perspective.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Connecticut</li>
<li>Missouri (État)</li>
<li>Pennsylvanie</li>
<li>Texas</li>
</region>
<settlement><li>Saint-Louis (Missouri)</li>
</settlement>
<orgName><li>École de médecine (Université Washington de Saint-Louis)</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Plamadeala, Victoria" sort="Plamadeala, Victoria" uniqKey="Plamadeala V" first="Victoria" last="Plamadeala">Victoria Plamadeala</name>
</region>
<name sortKey="Brower, Stacey L" sort="Brower, Stacey L" uniqKey="Brower S" first="Stacey L" last="Brower">Stacey L. Brower</name>
<name sortKey="Chan, John K" sort="Chan, John K" uniqKey="Chan J" first="John K" last="Chan">John K. Chan</name>
<name sortKey="Coleman, Robert L" sort="Coleman, Robert L" uniqKey="Coleman R" first="Robert L" last="Coleman">Robert L. Coleman</name>
<name sortKey="Gabrin, Michael J" sort="Gabrin, Michael J" uniqKey="Gabrin M" first="Michael J" last="Gabrin">Michael J. Gabrin</name>
<name sortKey="Kelley, Joseph L" sort="Kelley, Joseph L" uniqKey="Kelley J" first="Joseph L" last="Kelley">Joseph L. Kelley</name>
<name sortKey="Krivak, Thomas C" sort="Krivak, Thomas C" uniqKey="Krivak T" first="Thomas C" last="Krivak">Thomas C. Krivak</name>
<name sortKey="Powell, Matthew A" sort="Powell, Matthew A" uniqKey="Powell M" first="Matthew A" last="Powell">Matthew A. Powell</name>
<name sortKey="Rutherford, Thomas J" sort="Rutherford, Thomas J" uniqKey="Rutherford T" first="Thomas J" last="Rutherford">Thomas J. Rutherford</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000656 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000656 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25462203
   |texte=   A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25462203" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PittsburghV1

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

Serveur d'exploration sur Pittsburgh

A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.

A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.